Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eleva Appoints New Chief Medical Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Eleva Appoints New Chief Medical Officer

Dr. Martin Bauer, MD joins Eleva with over two decades of clinical development expertise.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Dr. Martin Bauer.

Eleva, a pioneer in unlocking difficult-to-produce biologics, has appointed Dr. Martin Bauer, MD, as its new Chief Medical Officer.

Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility. His roles include senior and leadership positions at Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. He is board-certified in Anesthesiology, Rescue Medicine, and Medical Informatics, and has over 10 years of experience working in academic hospitals. Martin Bauer earned his MD from Julius-Maximilians University of Würzburg, Germany.

“With the clinical trial start for our second fully owned drug development program on the horizon, we have decided to appoint an experienced Chief Medical Officer orchestrating all of these activities,” commented Björn Cochlovius Ph.D., CEO of Eleva. “Martin’s deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organization.”

Commenting on his appointment, Martin Bauer added: “I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programs and potentially new indications being explored. Our Factor H program in particular, has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics